+357 96 030922
info@marketpublishers.com

Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?

https://marketpublishers.com/r/B2F1E563672EN.html
Date: November 2011
Pages: 47
Price: US$ 595.00 (Single User License)
ID: B2F1E563672EN

Abstracts

Between now and 2019, a vast range of blockbuster drugs will go off patent, opening the floodgates in the EU to the biosimilars market. Already established there since 2006, biosimilars are set to be worth between $2.25 billion and $4.8 billion by 2015.

The potential is undeniable. Yet even in its advanced state compared to other regulated and unregulated markets, European biosimilars continue to be challenged by issues and hurdles, ranging from development and manufacturing to approval and opposition from originator companies. What lessons are there to be learned?

Report Overview

In Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?, FirstWord Dossier examines the emerging biosimilars market. The report, based on expert interviews and analysis, examines market differences across Europe and different therapeutic areas. The impact of biosimilars on originator companies—and their response—is discussed, as well as strategies biosimilar companies will engage in to expand their market share. And most importantly, the report offers insight into biosimilar deals and what the future holds in the EU.

Key features

Discussion of biosimilar markets in five geographic areas

Examination of key factors driving biosimilar uptake, including molecule and indications

+357 96 030922
info@marketpublishers.com

Detailed overview of development, manufacturing and approval issues in Europe

Insight into the position and protectionism of originator companies

Reporting on the role of collaboration

Key Benefits

Access to firsthand opinions from experts in the biosimilars and biotechnology industry

Review of deal-making data in biosimilars from a deal-making market leader

Forward-looking analysis of the future of biosimilars

Key Questions Asked

What are the challenges facing biosimilars in Europe?

How can biosimilars companies take market share in Europe?

How can originator biologics companies keep market share in Europe?

Which companies are collaborating over biosimilars development?

What deals are being made?

What's next for biosimilars?

Who Should Read This Report

+357 96 030922
info@marketpublishers.com

Market access directors and managers

Medical and scientific affairs professionals

Pricing and reimbursement teams

Intellectual property professionals

Patent analysts

Legal affairs teams

Regulatory and government affairs professionals

Key quotes

“The size of the global biologics market creates a massive opportunity for biosimilar developers to come in and take some of that market. The size of the prize in Europe will be significant, so there’s a big incentive for biosimilar companies to come in, develop these biosimilar products, and compete against the originator brands for market share.”
– Duncan Emerton, Head of Biosimilars, Datamonitor Healthcare Consulting
“I can't see the biosimilars market following the classic small molecule generic model where on day one, five molecules enter the market and the price drops to 20 percent of the brand. The economics just will not match those of the small molecule drugs.”
– Asa Cox, founder of biosimilarlicensing.com
“You can see that over time the biosimilar products have started to be accepted and used quite broadly in certain markets. There is a difference in uptake between countries – the uptake of biosimilars is not uniform across all the EU – and there is a difference between individual molecules as well.”
– Paul Greenland, EMEA Director of Biosimilars and Proprietary Marketing at Hospira

Expert Views

Carsten Thiel, Regional Vice President, Europe and Australia, Amgen

+357 96 030922
info@marketpublishers.com

Paul Greenland, EMEA Director of Biosimilars and Proprietary Marketing at Hospira

Duncan Emerton, Head of Biosimilars, Datamonitor Healthcare Consulting

Asa Cox, Founder of biosimilarlicensing.com

Lee Coney, Chief Scientific Officer, Biologics, Huntingdon Life Sciences

Jim Furniss, Director, Global Market Access Strategy, Bridgehead International

Andrew Teuten, Senior Partner, Sagittarius IP

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?

Product link: https://marketpublishers.com/r/B2F1E563672EN.html

Price: US$ 595.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/B2F1E563672EN.html